Concordia International (NASDAQ: CXRX) and Ra Pharmaceuticals (NASDAQ:RARX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.
Volatility and Risk
Concordia International has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Ra Pharmaceuticals has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500.
Valuation & Earnings
This table compares Concordia International and Ra Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Concordia International||$626.17 million||0.02||-$1.59 billion||$0.18||1.06|
|Ra Pharmaceuticals||$4.93 million||65.17||-$54.43 million||($2.41)||-4.13|
Ra Pharmaceuticals has lower revenue, but higher earnings than Concordia International. Ra Pharmaceuticals is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.
This table compares Concordia International and Ra Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for Concordia International and Ra Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ra Pharmaceuticals has a consensus target price of $21.20, indicating a potential upside of 113.07%. Given Ra Pharmaceuticals’ higher possible upside, analysts clearly believe Ra Pharmaceuticals is more favorable than Concordia International.
Insider & Institutional Ownership
6.1% of Concordia International shares are held by institutional investors. Comparatively, 75.5% of Ra Pharmaceuticals shares are held by institutional investors. 11.4% of Ra Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Ra Pharmaceuticals beats Concordia International on 8 of the 13 factors compared between the two stocks.
Concordia International Company Profile
Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Concordia International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International and related companies with MarketBeat.com's FREE daily email newsletter.